Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin-Secreting Cells | 3 | 2022 | 18 | 1.540 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 110 | 1.160 |
Why?
|
| Indoles | 4 | 2021 | 111 | 1.050 |
Why?
|
| Drug Design | 3 | 2021 | 63 | 0.920 |
Why?
|
| Cardiotonic Agents | 1 | 2025 | 28 | 0.910 |
Why?
|
| Myocardial Infarction | 2 | 2025 | 351 | 0.890 |
Why?
|
| Protective Agents | 2 | 2021 | 17 | 0.800 |
Why?
|
| PPAR gamma | 2 | 2021 | 29 | 0.790 |
Why?
|
| Molecular Probes | 1 | 2021 | 13 | 0.710 |
Why?
|
| Chelating Agents | 1 | 2021 | 22 | 0.710 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2021 | 37 | 0.700 |
Why?
|
| Technetium | 1 | 2021 | 43 | 0.700 |
Why?
|
| Pancreas | 1 | 2021 | 63 | 0.690 |
Why?
|
| Zinc | 1 | 2021 | 63 | 0.680 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2021 | 39 | 0.660 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 215 | 0.630 |
Why?
|
| Benzamides | 1 | 2019 | 39 | 0.620 |
Why?
|
| Endoribonucleases | 3 | 2025 | 10 | 0.600 |
Why?
|
| Molecular Structure | 3 | 2021 | 245 | 0.350 |
Why?
|
| Structure-Activity Relationship | 3 | 2020 | 209 | 0.340 |
Why?
|
| Nitro Compounds | 2 | 2020 | 10 | 0.340 |
Why?
|
| Apoptosis | 4 | 2022 | 780 | 0.330 |
Why?
|
| Benzopyrans | 2 | 2020 | 22 | 0.330 |
Why?
|
| Mice | 7 | 2025 | 4808 | 0.320 |
Why?
|
| Insulin | 2 | 2021 | 325 | 0.310 |
Why?
|
| Tissue Distribution | 2 | 2025 | 137 | 0.270 |
Why?
|
| Ligands | 2 | 2025 | 178 | 0.260 |
Why?
|
| Insulin Resistance | 2 | 2025 | 176 | 0.240 |
Why?
|
| Animals | 7 | 2025 | 10699 | 0.240 |
Why?
|
| Phosphatidylethanolamines | 1 | 2025 | 26 | 0.230 |
Why?
|
| Phosphatidylcholines | 1 | 2025 | 45 | 0.230 |
Why?
|
| Thermogenesis | 1 | 2025 | 19 | 0.230 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 686 | 0.220 |
Why?
|
| Polyethylene Glycols | 1 | 2025 | 101 | 0.220 |
Why?
|
| Liposomes | 1 | 2025 | 145 | 0.210 |
Why?
|
| Myocardium | 1 | 2025 | 196 | 0.210 |
Why?
|
| Cholesterol | 1 | 2025 | 203 | 0.210 |
Why?
|
| Adipose Tissue | 1 | 2025 | 197 | 0.200 |
Why?
|
| Drug Delivery Systems | 1 | 2025 | 236 | 0.190 |
Why?
|
| Unfolded Protein Response | 1 | 2022 | 25 | 0.190 |
Why?
|
| Triazoles | 1 | 2022 | 16 | 0.190 |
Why?
|
| Macrophages | 1 | 2025 | 305 | 0.190 |
Why?
|
| Obesity | 2 | 2025 | 701 | 0.180 |
Why?
|
| Cell Survival | 2 | 2020 | 419 | 0.180 |
Why?
|
| Adipose Tissue, White | 1 | 2021 | 24 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 612 | 0.180 |
Why?
|
| Colchicine | 1 | 2020 | 16 | 0.170 |
Why?
|
| Coronary Vessels | 1 | 2022 | 154 | 0.170 |
Why?
|
| Tubulin | 1 | 2020 | 32 | 0.170 |
Why?
|
| Tubulin Modulators | 1 | 2020 | 17 | 0.170 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2021 | 98 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 251 | 0.160 |
Why?
|
| Solubility | 1 | 2019 | 73 | 0.160 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 1508 | 0.160 |
Why?
|
| Amino Acids | 1 | 2019 | 85 | 0.150 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 122 | 0.150 |
Why?
|
| Models, Molecular | 1 | 2019 | 453 | 0.140 |
Why?
|
| Humans | 5 | 2022 | 28884 | 0.110 |
Why?
|
| Mice, Obese | 2 | 2025 | 22 | 0.100 |
Why?
|
| Male | 2 | 2025 | 13934 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 103 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 1658 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2020 | 825 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 1351 | 0.060 |
Why?
|
| Diet, High-Fat | 1 | 2025 | 144 | 0.050 |
Why?
|
| Streptavidin | 1 | 2022 | 11 | 0.050 |
Why?
|
| Fibronectins | 1 | 2022 | 28 | 0.050 |
Why?
|
| Glucaric Acid | 1 | 2022 | 10 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 27 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 32 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2021 | 9 | 0.050 |
Why?
|
| 3T3-L1 Cells | 1 | 2021 | 30 | 0.040 |
Why?
|
| Necrosis | 1 | 2022 | 85 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 79 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2021 | 60 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2022 | 145 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 100 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 117 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 202 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 53 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2020 | 60 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2020 | 67 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 32 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2020 | 223 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2021 | 1022 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 634 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 867 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 344 | 0.030 |
Why?
|